Office of New Drugs director returns
FDA Office of New Drugs Director John Jenkins returns to his position at the agency following a personal leave. OND Deputy Director Sandra Kweder served as acting director during Jenkins' absence. Kweder represented the office on the decision to request a "black box" warning on antidepressant labeling and testified on behalf of FDA at the Senate Finance Committee's hearing on the Vioxx withdrawal (1"The Pink Sheet" Oct. 18, 2004, p. 3). Jenkins represented OND on a Dec. 17 conference call on Celebrex safety data...
You may also be interested in...
FDA's proposed "black box" warning for all antidepressants would likely mean an end to television ads for the products
The Honest Company’s new digital and strategy chief joins from Amazon.com where he led development of home security systems and contactless, in-garage delivery for more than 50m Amazon Key customers. More cosmetics people news, including new supply chain and sustainability leadership at the Independent Beauty Association.
Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.